Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yeah. Like so-called "independent" BOD's do such a good job of keeping salaries in check. Riiiighttt....
The fact is that our management team is making substantial progress. Therefore I have no problem with the raises.
Brenum said...
...To answer your concerns about the BOD before, Leo and Menon are the board. They elected to pay themselves more. ...
@MineAllMine.
LOL! Carry on...
I hope you are being sarcastic. Because if you really believed that the symbol was an accurate depiction of a molecule of anatabine, I don't know what to say to you. Exactly what difference would it have made to you if the symbol was an accurate depiction? This has got to be the most ridiculous argument yet manufactured for suing this company. And that is saying something...
MineAllMine said...
I am going to join the law suit because the Anatabloc logo does not look exactly like a molecule of anatabine.
ISCO GREEN AT THE END OF THE DAY !
Thanks
I'm not seeing that PR. Can you post a link?
ISCO IN THE GREEN AT LUNCH!
The fundamental picture remains intact, at least according to this article...
http://www.trustintelligence.com/forum/viewtopic.php?pid=103524#p103524
There is a link at the bottom of the screen that will take you to a 9 page pdf.
According to him, the company's products have a potential Net Present Value of over $26 billion dollars. However, the company has only increased it's target number for selling the company from $3 billion to $4 billion (or $20 per fully diluted share).
So a big pharma could potentially get a $26 billion value for $4 billion. (Pfizer has two of it's cancer specialist on PVCT's advisory board.) That is one heck of a discount for any potential suitor.
ONE BIG REASON FOR ISCO's POTENTIAL IS THAT MANAGEMENT OWNS A LOT OF SHARES!
Volume dried up today on pretty much all of my Biotechs. We'll probably never know why...
mattp said...
Volume is drying up on this one. I expect it to continue to fall until they release some big news.
That's what I was wondering...
no posts since before 9pm last night? where did everyone go?
I don't have CUR or ONCS. I have the position I want in GALT and NNVC, although I might add some more if the right opportunity presented itself.
I just started last fall accumulating a position in PVCT and CTIX and am probably about halfway to where I want to be, particularly with CTIX.
I plan to sign up with Patrick again... when one of the above makes a move.
ONE REASON WHY ISCO's SHARE PRICE WILL RISE!
As modrica said...
for the first 3 quarters 2013 ISCO had 4,4 millions revenues
for the first 3 quearters 2013 gross profits were 3,3 millions
these are all easily verifiable facts
in fact read last 10q :
yahoo.brand.edgar-online.com/displayfilinginfo.aspx?FilingID=9606151-918-342544&type=sect&dcn=0001193125-13-439222
thanks
gl
mod
ISCO's SHARE PRICE WILL RISE WITH ALL THE PROGRESS ISCO IS MAKING!
as modrica said...
for the first 3 quarters 2013 ISCO had 4,4 millions revenues
for the first 3 quearters 2013 gross profits were 3,3 millions
these are all easily verifiable facts
in fact read last 10q :
yahoo.brand.edgar-online.com/displayfilinginfo.aspx?FilingID=9606151-918-342544&type=sect&dcn=0001193125-13-439222
thanks
gl
mod
I agree. I would also add PVCT, ISCO, and even STSI to your list. I think that GALT and PVCT are most likely to pop first with NNVC not far behind (assuming tox studies get completed). But CTIX has so many very hot irons in the fire, 2014 should be good for it as well.
DirectionalDriller said...
GALT is also my best performer and has good odds to continue upward through 2014. I also like NNVC I think is better odds of success, and the some of the other Cox ones CTIX, BTX, INO...............etc.
All can go 10X+ in the next few years.
I think odds are better than 100% if you own only 4 or 5 of them, that one with be up more than 10X.
Like I think Biotech2010 said about Poker odds. These are all really good for risk/reward.
NOTHING BETTER THAN ISCO HAVING FAST GROWING REVENUES AND NOT HAVING TO BE SUPPORTED BY DILUTION OFF THE SHAREHOLDERS BACK! THE ISCO MANAGEMENT ARE VERY PRACTICAL LEADERS! DONT BUY INTO THE ISCO FUD!
As I said, Revenues ARE significant AND increasing.
Modrica said...
ISCO revenues q by q in 2013
yahoo.brand.edgar-online.com/displayfilinginfo.aspx?FilingID=9606151-918-342544&type=sect&dcn=0001193125-13-439222
last 4 quarters :
December ,31,2012 = 1 247 000 ( gross profit 315 K )
March , 31 , 2013 = 1 285 000 ( gross profit 951 K ))
June , 30 , 2013 = 1 457 000 ( gross profit 1,13 mill.)
September ,30 , 2013 = 1 670 000 ( gross profit 1,223 mill.)
as we can see revenues grew 35 % in 2013 and whats most important is that gross profits grew 300% which means ISCO is managing business better and are able to lower expenses while at the same time increasing sales
very good sign
saying that ISCO has no revenues is the same as saying that water is not wet - untrue
imo
gl
mod
Revenues ARE significant AND increasing.
Modrica said...
ISCO revenues q by q in 2013
http://yahoo.brand.edgar-online.com/displayfilinginfo.aspx?FilingID=9606151-918-342544&type=sect&dcn=0001193125-13-439222
last 4 quarters :
December ,31,2012 = 1 247 000 ( gross profit 315 K )
March , 31 , 2013 = 1 285 000 ( gross profit 951 K ))
June , 30 , 2013 = 1 457 000 ( gross profit 1,13 mill.)
September ,30 , 2013 = 1 670 000 ( gross profit 1,223 mill.)
as we can see revenues grew 35 % in 2013 and whats most important is that gross profits grew 300% which means ISCO is managing business better and are able to lower expenses while at the same time increasing sales
very good sign
saying that ISCO has no revenues is the same as saying that water is not wet - untrue
imo
gl
mod
"As I said before, increasing revenues mean little or no dilution..."
And the truth shall set you free!
As I said before, increasing revenues mean little or no dilution...
Mod said...
revenues q by q in 2013
last 4 quarters :
December ,31,2012 = 1 247 000 ( gross profit 315 K )
March , 31 , 2013 = 1 285 000 ( gross profit 951 K ))
June , 30 , 2013 = 1 457 000 ( gross profit 1,13 mill.)
September ,30 , 2013 = 1 670 000 ( gross profit 1,223 mill.)
as we can see revenues grew 35 % in 2013 and whats most important is that gross profits grew 300% which means ISCO is managing business better and are able to lower expenses while at the same time increasing sales
very good sign
imo
gl
I believe that the old business plan was to concentrate resources solely on getting Flucide approved. As I recall, that PRV was to be for Denguecide. However as I understand it, one of the reasons for the recent secondary was to acquire the funding necessary to advance our other "cides" on a parallel track.
I would think that as soon as the tox studies are complete, several of our "cides" will be able to move forward.
Smooth said...
Are we still in the running for a PRV...priority review voucher? This could be worth many hundreds of millions if my recollection is correct...anyone?
It's good to see a company fighting back against those criminals.
Centillion said...
The Cellceutix Berlin listing: COC is of particular concern to me because of the following statement from Dephasium Corp and others.
Dephasium Corp. Comments on Unauthorized Listing on Boerse Berlin Stock Exchange
“The Boerse Berlin Stock Exchange is one of the few stock exchanges in the world that allows listing and trading of a company's stock without the consent or authorization of the company being listed. This practice may facilitate both domestic and foreign brokers in circumvent restrictions imposed by both the Financial Industry Regulatory Authority ("FINRA") and the Securities and Exchange Commission relating to the trading practice referred to as "naked short selling". Short selling is a trading practice whereby investors borrow stock from a broker to sell in the hopes that the stock price will decline before they have to return the share to the broker to cover their position. Many naked short selling attacks involve groups of people working in concert to manipulate the market in order to force a company's share price lower for personal profit. Naked short sellers can list an OTCBB or OTCQB traded company on the BBSE in order to delay delivery of shares under the short position”.
http://finance.yahoo.com/news/dephasium-corp-comments-unauthorized-listing-133600081.html
Perhaps it could do both...
farrell90 said...
The FDA has two choices. It could extend the study to determine DLT and MTD or it could approve FDA phase 2 studies for different indications using the doses in the last cohort completed.
Management has a winner in PV-10. The next 4 months will tell the tale. In the meantime....
Increasing revenues mean little or no dilution...
Mod said...
revenues q by q in 2013
last 4 quarters :
December ,31,2012 = 1 247 000 ( gross profit 315 K )
March , 31 , 2013 = 1 285 000 ( gross profit 951 K ))
June , 30 , 2013 = 1 457 000 ( gross profit 1,13 mill.)
September ,30 , 2013 = 1 670 000 ( gross profit 1,223 mill.)
as we can see revenues grew 35 % in 2013 and whats most important is that gross profits grew 300% which means ISCO is managing business better and are able to lower expenses while at the same time increasing sales
very good sign
imo
gl
Increasing revenues mean little or no dilution...
Mod said...
revenues q by q in 2013
last 4 quarters :
December ,31,2012 = 1 247 000 ( gross profit 315 K )
March , 31 , 2013 = 1 285 000 ( gross profit 951 K ))
June , 30 , 2013 = 1 457 000 ( gross profit 1,13 mill.)
September ,30 , 2013 = 1 670 000 ( gross profit 1,223 mill.)
as we can see revenues grew 35 % in 2013 and whats most important is that gross profits grew 300% which means ISCO is managing business better and are able to lower expenses while at the same time increasing sales
very good sign
imo
gl
ISCO has significant revenues so Mac is correct.
Mac said...
yes... ISCO has significant revenues... which is practically unheard of for a developmental phase biotech... and those revenues have been growing quarter over quarter... thanks for keeping it real here...
In response to your question, I have no doubts that the science is real.
ohibbs said...
The question is" is it real or is it "pseudo" science?
Thank you modrica for providing the correct information.
Mod said...
ISCO revenues 3rd q 2013 1,67 millions $
first 3 quarters 2013 = 4,4 millions revenues
proof here:
yahoo.brand.edgar-online.com/displayfilinginfo.aspx?FilingID=9606151-918-342544&type=sect&dcn=0001193125-13-439222
this is fact , isco has more than 5 millions yearly revenues
gl
mod
I think a better suggestion would be to publish more "before, during, & after" photo arrays like this one.
http://4.bp.blogspot.com/-4P52Ani3TkU/UpaYBkCDzUI/AAAAAAAAGI4/csuxLjbE9xg/s400/tissueSparing.png
A dozen more examples like this would be hard to ignore...
Hounddogg said...
There's a suggestion on the Investor Village board that management purchase PVCT stock. I think that's a good idea.
You are correct Karin. As you stated there are no revenues from "current operations in therapeutic research and development." But that is not the same as saying that there are "no revenues" at all.
ISCO is a better choice than other stem cell companies for my portfolio in part because they do have two separate and rapidly growing revenue streams. Those revenue streams may not be generated from "current operations in therapeutic research and development" but they did originate from ISCO's R&D and they are significant.
As always, do your own DD and don't be fooled by capitalized FUD.
Exactly! With that growing revenue stream and enough cash on hand to take us through 2014, ISCO is well positioned.
Karin said...
That growing revenue stream is almost unheard of for a company at this stage. Those revenues will reduce the need for dilution as time passes and they continue to grow.
Besides the growing revenue stream, the Parkinson's trial is the next major price driver. And it could be MAJOR...
1iftrue said...
AGREE with waiting for Parkinson trial here. Shares are cheap here imo.
While this law has been on the books for awhile, the FDA has not been enforcing it. The FDA has apparently not even implemented (or written?) the regulations necessary to enforce it. Further there has been a years long effort to overturn the law and/or stop the FDA from implementing this section of the law. Several years ago when I was participating in the letter writing campaign to congress, Anatabloc did not even exist. As I recall, the law impacts any supplement brought to market since 1994 and CoQ10 was the primary supplement I was concerned about at the time.
The fear of those in the supplement industry is that any new supplement brought to market since 1994 would be required to go thru drug like testing. This would drive the price so high as to make those supplements unaffordable. Or worse, since it is very hard (many times impossible) to acquire patent protection for a supplement, why would any company fund efficacy studies that their competitors could then use for free. This would mean that new supplements would never make it to the US market. The other factor was the concern that every new combination of supplements formulated since 1994 would be required to also go through such testing. The "new" FDA has the potential to cripple the vitamin and supplement industry thru disincentives and substantially increased cost.
If all he FDA was trying to do was quality control of the ingredients and final product, I would support that effort. But I fear that this is the opening shot in a whole new arena of bureaucracy and regulation.
The current negative publicity environment created by AF and his minions along with the political fiasco, apparently made anatabine the low hanging fruit the bureaucrats at the FDA were looking for to begin this long planned expansion of their authority.
Dynarod said...
Can someone please answer this question? I though we had FDA savy guys on our team. What bright spark in our companywas completely unaware of the fact that new supplements need to be preapproved by the FDA?
Are these photos of a PV-10 patient?
http://4.bp.blogspot.com/-4P52Ani3TkU/UpaYBkCDzUI/AAAAAAAAGI4/csuxLjbE9xg/s400/tissueSparing.png
I agree with your assessment.
Modrica said...
ISCO has enough cash (funds) secured in December 10.25 millions $ financing (with minimal dilution) to see them through 2014 and 2015
revenues are increasing q to q so another source of cash
compare ISCO to close competitors in the field (actc,gern,stem,btx,etc...) then compare market caps , funds on hand and revenues and you'll see how undervalued isco at the moment is
it will take patience and once trials are underway second half of 2014 we'll be looking at way higher pps
obviously this is not instant grat stock at the moment but i have mountain of patience
d stage stock with more than 5 millions in revenues and increasing
sure bet
in my opinion
gl
mod
Good information. I think that 2014 is going to e a good year!
Karin said...
$ISCO - Efficacy Study of Stem Cell-Derived Neuronal Cells for the Treatment of Parkinson's Disease
March 22, 2013
b2icontent.irpass.cc/1468%2F144195.pdf?AWSAccessKeyId=1Y51NDPSZK99KT3F8VG2&Expires=1380969148&Signature=3jESteKNomjh21IvkAadlrCDMfU%3D
The current primate trial was at the request of the FDA to enable the filing of the IND. Here's the PR dealing with it:
International Stem Cell Corporation Initiates IND-Enabling Study in Parkinson's Disease Program
May 30, 2013
http://www.internationalstemcell.com/profiles/investor/ResLibraryView.asp?ResLibraryID=63010&GoTopage=2&Category=958&BzID=1468&G=583
Quote:
CARLSBAD, CA -- (Marketwired) -- 05/30/13 -- International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) a California-based biotechnology company developing novel stem cell based therapies, announced today the initiation of its IND-enabling pharmacology and toxicology non-human primate studies, under the direction of Yale School of Medicine Professor D. Eugene Redmond Jr. MD, the internationally recognized neurosurgeon and a leader in the use of stem cells for the treatment of Parkinson's disease.
The studies will use non-human primates with moderate to severe Parkinson's disease symptoms to assess the safety and functional efficacy of ISCO's proprietary stem cell-derived neuronal cells. The endpoints of these multi-dose studies include determining cell fate, biodistribution and primate behavioral evaluations using a standardized rating scale to assess potential extrapyramidal side effects associated with the cell engraftment. The first, interim results are expected in Q4 of 2013 with the final results available in Q2 of 2014.
Leading the studies will be Prof. Redmond, a recognized expert in the use of transplanted neural cells to treat parkinsonism in primates and the development of effective replacement strategies using stem cell derived neurons. In his career of over 25 years, Prof. Redmond has made many significant contributions in the field of cellular repair in the nervous system for Parkinson's disease. His accomplishments include establishing one of the first preclinical models for Parkinson's disease in primates, the first successful transplantation of fetal tissue into the brain of a primate and one of the first clinical studies of fetal tissue in Parkinson's patients.
"Building on the results from the successful primate and rodent studies we reported earlier this year, we expect these formal studies to be the final step allowing ISCO to file an IND for Parkinson's disease," said Dr. Ruslan Semechkin, Vice President of Research and Development. "As one of the leaders in this field, it's tremendously exciting for ISCO to have such an experienced and influential clinical scientist as Prof. Redmond to direct this research. His clinical experience will be invaluable as we prepare both our IND submission to the FDA and the subsequent phase I clinical trial," Dr. Semechkin continues.
The revenues generated from their two subsidiaries will lower the amount needed for the trial. And, we should see whether or not revenues are continuing to grow in early November when their next filing is due.
I'm in accumulation mode before it makes any major moves. It's a risk, but, one I've decided is worth taking. The dilution they've had isn't that bad when one considers the heavy inside ownership. There's been a lot of self funding here.
Good luck to all. ;)
ISCO's finances are in good shape so you are right DrKaz.
Bankruptcy requires income and assets to be exceeded by liabilties,... and more specifically the assets and income must be exceeded by liabilities held by creditors who do not forsee future ability to cover the liabilities.
Since ISCO is in no way in that particular financial situation - you may be waiting a long time to see this company in bankruptcy.
I would suggest you not hold your breath while waiting for that particular event to happen.
Revenue generation from the revenue generating Subs is increasing quarter over quarter,.... and the rate of that increase does not appear to be leveling off at this point either.
Current finances for the parent company are actually quite good for a start-up biotech/medtech company at its stage of development.
This is good info Modrica. I just read it again. Strong stuff...
"ISCO secured almost 16 millions $ since July , that will be enough till 2016 at least
people read from conference calls :
<< read the fact from cc :
<< in July we raised approximately $3 million, most of which came from a group of new investors new to ISCO. The capital will be used to fund our R&D programs, primarily our Parkinson's disease program where we intend to start a clinical trial in 2014.
As part of the offering, we also issued B Warrants which expired in October of this year, and we now have, through the execution of these B Warrants, raised a total of about $5.45 million from this transaction which along with our continued ability to manage our burn rate successfully downwards, now funds the Company well into 2014. >>
so funds raise in July will get ISCO well into 2014
In December ISCO secured another 10.25 millions $ from With Lincoln Park Capital Fund, LLC
10.25 millios will be with minimal dilution because there are no warrants or convertibles
The Company controls the timing and amount of any future investment and LPC is obligated to make such purchases.
read :
<< There are no upper limits to the price LPC may pay to purchase ISCO common stock .... and .... LPC has agreed not to cause or engage in any manner whatsoever, any direct or indirect short selling or hedging of the Company's shares of common stock >>
ih.advfn.com/p.php?pid=nmona&article=60351106
these are all facts and not forward looking statements
on top 5 millions yearly revenues and increasing, revenues has increased for last 4 quarters and trend is expected to continue
ISCO in 2013 had more than 3 millions in gross profits
imo
gl
mod"
You said it best.
"ISCO is almost debt free entity (check financials) with lots of cash/funds into 2016
these are facts
next leg up should be coming real soon"